Chun Helen M, Milligan Kyle, Agyemang Elfriede, Ford Nathan, Rangaraj Ajay, Desai Shalini, Wilder-Smith Annelies, Vitoria Marco, Zulu Isaac
Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, USA.
Peraton, Herndon, Virginia, USA.
Open Forum Infect Dis. 2022 Nov 8;9(11):ofac579. doi: 10.1093/ofid/ofac579. eCollection 2022 Nov.
HIV infection is a significant independent risk factor for severe coronavirus disease 2019 (COVID-19) disease and death. We summarize COVID-19 vaccine responses in people with HIV (PWH). A systematic literature review of studies from January 1, 2020, to March 31, 2022, of COVID-19 vaccine immunogenicity in PWH from multiple databases was performed. Twenty-eight studies from 12 countries were reviewed. While 22 (73%) studies reported high COVID-19 vaccine seroconversion rates in PWH, PWH with lower baseline CD4 counts, CD4/CD8 ratios, or higher baseline viral loads had lower seroconversion rates and immunologic titers. Data on vaccine-induced seroconversion in PWH are reassuring, but more research is needed to evaluate the durability of COVID-19 vaccine responses in PWH.
人类免疫缺陷病毒(HIV)感染是严重的2019冠状病毒病(COVID-19)发病和死亡的一个重要独立危险因素。我们总结了HIV感染者(PWH)对COVID-19疫苗的反应。对2020年1月1日至2022年3月31日期间多个数据库中关于PWH对COVID-19疫苗免疫原性的研究进行了系统的文献综述。对来自12个国家的28项研究进行了审查。虽然22项(73%)研究报告称PWH中COVID-19疫苗的血清转化率较高,但基线CD4细胞计数较低、CD4/CD8比值较低或基线病毒载量较高的PWH血清转化率和免疫滴度较低。PWH中疫苗诱导的血清转化数据令人放心,但需要更多研究来评估PWH对COVID-19疫苗反应的持久性。